We serve BOC-ALANINE-1-HYDROXYSUCCINIMIDE ESTER CAS:3392-05-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: Succinimido (S)-2-[(tert-butoxycarbonyl)amino]propionate
CAS.NO: 3392-05-0
Molecular Formula:C12H18N2O6
Molecular Weight: 286.28100
Synonyms:
Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, 2,5-dioxo-1-pyrrolidinyl ester
Boc-L-alanine N-succinimidyl ester,Boc-L-alanine hydroxysuccinimide ester
BOC-D-ALANINE-HYDROXYSUCCINIMIDE ESTER
Boc-Ala-OSu
Boc-L-alanineydroxysuccinimidester
N-SUCCINIMIDYL N-TERT-BUTYLOXYCARBONYL-L-ALANINATE
Succinimido (S)-2-[(Tert-Butoxycarbonyl)Amino]Propionate
BOC-L-ALANINE-HYDROXYSUCCINIMIDESTER
N-tert-butoxycarbonyl-L-alanine-N-hydroxysuccinimide ester
BOC-L-ALA-OSU
BOC-D-ALANINE-OSU
BOC-ALANINE-1-HYDROXYSUCCINIMIDE ESTER
Physical and Chemical Properties:
Density: 1.3±0.1 g/cm3
Boiling point:/
Melting point: 161-163 °C
Flash point: /
Refractive index: 1.511
Specification:
Appearance: White powder
Purity:≥99%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store at -20ºC.Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:pharmaceutical intermediates.
Contact us for information like Succinimido (S)-2-[(tert-butoxycarbonyl)amino]propionate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,BOC-ALANINE-1-HYDROXYSUCCINIMIDE ESTER physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,BOC-L-ALA-OSU Use and application,Succinimido (S)-2-[(tert-butoxycarbonyl)amino]propionate technical grade,usp/ep/jp grade.
Related News: What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.2-chloro-4-(naphthalen-2-yl)-6-phenyl-1,3,5-triazine manufacturer Who is at risk of infection? People of all ages can be infected with the virus, but older people and those with pre-existing medical conditions are especially vulnerable to severe complications.2,4,6-Trimethybromombenzene supplier Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.2-thioladenosine vendor At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.
